n-Lorem Foundation Welcomes New Member Alan Lotvin to Its Board of Dir...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: May 20, 2024

Butterfly Kisses Ultrasound Imaging Center Opens its Doors in Swedesboro, NJ! • NEW YORK'S ONLY OUTPATIENT PROGRAM FOR REDUCING ALLERGIC REACTIONS TO CANCER TREATMENTS HITS NEW CARE MILESTONE • Operation Homefront Receives National Recognition for Impact and Innovation Campaigns • Jeepers Go Topless to Raise Money for Charity • MetLife Launches My Leave Navigator to Support Employees Navigating Leave • VinciVR, New York Offshore Wind Developers, and NYC Colleges launch Immersive Education Week for Wind Careers • Ameresco Awarded $21 Million Contract to Illuminate Henderson's Streets with State-of-the-Art LED Technology • Electrosoft CEO Dr. Sarbari Gupta Honored with 2024 WIT Leadership Award • American Camp Association Awarded $2.25 Million to Create, Improve, and Expand Leadership Pathways at Camp for Young People of D • This Father’s Day, Staples Is Helping Dads ‘Cut the Cord’ With Their Box of Old Cables to Create the First-of- • 4 Organizations Partner to Champion Safe Sleep for Babies • Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF) • Millennial & Gen X Moms Struggle with the Mental Load, Spending a Staggering 520 Hours Per Year on Invisible Labor • Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting • Coursera Announces Four New Entry-Level Certificates from Microsoft to Help Learners Pursue High-demand Jobs • Bumble Inc. Signs Agreement to Acquire Group and Community App Geneva • IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Health • ANU - Museum of the Jewish People in Tel Aviv, Israel Receives $1.5 Million from the Mike and Sofia Segal Foundation • Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COV • Animal Alerts powered by PetPace™ Turns Pet Health Data into Earthquake Warnings

www.blackradionetwork.com > n-Lorem Foundation Welcomes New Member Alan Lotvin to Its Board of Directors

n-Lorem Foundation Welcomes New Member Alan Lotvin to Its Board of Directors

SAN DIEGO , May 09 /Businesswire/ - n-Lorem, a nonprofit foundation, discovering, developing and providing experimental antisense oligonucleotide (ASO) medicines for nano-rare patients (1 to 30 patients worldwide) for free, for life, today announced that Alan Lotvin, M.D., has joined its Board of Directors.

“Stan and the entire n-Lorem team have created an organization unlike any I have been involved in. With a commitment to quality and patient safety at the top of any decision, n-Lorem has implemented an efficient and scalable process to discover, develop and provide personalized ASO medicines to patients today,” Dr. Lotvin said. “This work has already changed the lives of many people who have had no other options available to them. It is work like this that led me to get into medicine and work to bring new advancements to the world. I look forward to joining the Board of Directors and helping n-Lorem continue to identify and implement creative solutions to reach even more nano-rare patients.”

“At n-Lorem, we have expanded years ahead of where we anticipated due to the overwhelming demand from the nano-rare community. As we identify and implement efficiencies in one area of the organization, more challenges present. Alan’s deep understanding and experience with healthcare coverage and insurers will help inform our efforts as we scale to meet a growing need from the nano-rare community,” said Stanley T. Crooke, M.D., Ph.D., Founder, Chairman and CEO, n-Lorem Foundation. “While we are currently helping individual patients, we will one day be able to treat thousands of patients with nano-rare conditions. Our Board is going to be an integral part of ensuring we can reach that goal.”

Learn more about n-Lorem’s mission at www.nlorem.org, and please consider giving to n-Lorem to bring hope, possibility and treatment options to these needy patients and families.

Watch: n-Lorem Foundation: Offering Hope and Help to Nano-rare Patients

Watch: n-Lorem Foundation Delivers Hope and Treatment for Patient with Nano-Rare Disease

About Alan Lotvin

Dr. Lotvin is an interventional cardiologist with extensive experience in pharmacy benefit management and specialty pharmacy industries. Alan Lotvin co-founded Sequel, a company developing state-of-the-art insulin delivery technologies. Prior to Sequel, Dr. Lotvin served as executive vice president of CVS Health and president of CVS Caremark, the company’s pharmacy benefits management business. He was also the chief transformation officer and executive vice president of CVS Speciality, the specialist pharmacy of CVS Health, and held roles in ICORE Healthcare and Medo Health Solutions. Dr. Lotvin started his career as a cardiologist in New Jersey. Dr. Lotvin holds a Masters Degree in Medical Informatics from Columbia University, a Medical Degree from the State University of New York Health Sciences Center in Brooklyn, and a bachelor’s degree in biochemistry from Stony Brook University.

About n-Lorem

n-Lorem Foundation is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat nano-rare patients diagnosed with diseases that are the result of a single genetic defect unique to only one or very few individuals. Nano-rare patients describe a very small group of patients (1-30 worldwide) who, because of their small numbers, have few if any treatment options. n-Lorem Foundation was created to provide hope to these nano-rare patients by developing individualized ASO medicines, which are short strands of modified DNA that can specifically target the transcripts of a defective gene to correct the abnormality. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. To date, n-Lorem received over 260 applications for treatment with more than 120 nano-rare patients approved. n-Lorem was founded by Stanley T. Crooke, M.D., Ph.D., former chairman and CEO of Ionis Pharmaceuticals, who founded Ionis Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. Follow us on Twitter, Facebook, LinkedIn and YouTube.

Learn more about n-Lorem’s mission at www.nlorem.org, and please consider giving to n-Lorem to bring hope, possibility and treatment options to these patients and families in need.